TY - CHAP M1 - Book, Section TI - Early-Stage and Locally Advanced Breast Cancer A1 - Smith-Graziani, Demetria A1 - Chavez-MacGregor, Mariana A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. A2 - Rieber, Alyssa G. PY - 2022 T2 - The MD Anderson Manual of Medical Oncology, 4e AB - KEY CONCEPTSA multidisciplinary approach is of upmost importance, especially with regard to planning and coordinating multimodality therapy. It is important to involve surgical and radiation oncology colleagues early to determine the best treatment plan.Choice of systemic therapy is ultimately guided by biomarker status of the patient's tumor.Whereas patients with hormone receptor–positive cancers should receive endocrine therapy, those with human epidermal growth factor receptor 2 (HER2)–positive cancers should receive anti-HER2 targeted therapy.Genomic assays can help assess the benefit of adjuvant chemotherapy in patients with hormone receptor–positive/HER2-negative breast cancer.All women with node-positive disease and a significant percentage of women with node-negative tumors that are hormone receptor negative or larger than 1 cm in size benefit from chemotherapy. Those with HER2-positive breast cancer need to receive anti-Her2 therapyChemotherapy is the cornerstone of treatment for patients with triple-negative breast cancer (TNBC).Preoperative or neoadjuvant chemotherapy should be administered in most patients with HER2-positive or TNBC. The presence of a pathological complete response or residual disease has important prognostic implications but now allows us to identify patients that will benefit from additional adjuvant treatment. SN - PB - McGraw Hill Education CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1190836301 ER -